Veralipride

Summary

Veralipride (CHEMBL2105581) is an approved small molecule (ATC N05AL06); indicated across 2 conditions including psychotic disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N05AL06
• Indications: 2 conditions
• Chemistry: 383.5 Da · C17H25N3O5S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2105581
Name	Veralipride
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	47979
ATC	N05AL06
Molecular formula	C17H25N3O5S
Molecular weight	383.5
InChIKey	RYJXBGGBZJGVQF-UHFFFAOYSA-N

SMILES: COC1=CC(=CC(=C1OC)C(=O)NCC2CCCN2CC=C)S(=O)(=O)N

IUPAC name: 2,3-dimethoxy-N-[(1-prop-2-enylpyrrolidin-2-yl)methyl]-5-sulfamoylbenzamide

Also known as: Agradil, Agreal, Veraliprida, Veralipride, SID144205502, VERALIPRIDE, veralipride

Patent coverage: 325 distinct patent families (1,165 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 22 (assay-derived). Sample: Alpha-2A adrenergic receptor, Alpha-2C adrenergic receptor, Alpha-2B adrenergic receptor, Carbonic anhydrase 2, D(1A) dopamine receptor, 5-hydroxytryptamine receptor 1A, D(2) dopamine receptor, 5-hydroxytryptamine receptor 2A, Sodium-dependent serotonin transporter, Carbonic anhydrase 7.

Bioactivity

ChEMBL activities: 18 potent at pChembl ≥ 5 of 22 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
DRD3	8.52	AC50	3	nM	CHEMBL_ACT_25193917
DRD1	7.89	AC50	13	nM	CHEMBL_ACT_25115870
CA12	7.62	Ki	23.9	nM	CHEMBL_ACT_29168477
CA9	7.51	Ki	31.1	nM	CHEMBL_ACT_29168474
CA5B	7.33	Ki	46.6	nM	CHEMBL_ACT_29168465
DRD2	7.24	AC50	57.1	nM	CHEMBL_ACT_25140731
CA6	7.19	Ki	65.1	nM	CHEMBL_ACT_29168468
CA13	7.04	Ki	91.9	nM	CHEMBL_ACT_29168480
CA14	6.8	Ki	157.7	nM	CHEMBL_ACT_29168483
CA2	6.39	Ki	405.7	nM	CHEMBL_ACT_29168453
CA5A	6.16	Ki	700.6	nM	CHEMBL_ACT_29168462
CA7	6.01	Ki	978.2	nM	CHEMBL_ACT_29168471
CA4	5.94	Ki	1138	nM	CHEMBL_ACT_29168459
CA1	5.57	Ki	2723	nM	CHEMBL_ACT_29168450
ADRA2B	5.5	AC50	3200	nM	CHEMBL_ACT_25144087
HTR1A	5.44	AC50	3600	nM	CHEMBL_ACT_25216285
KCNH2	5.12	AC50	7600	nM	CHEMBL_ACT_25118430
ADRA2C	5	AC50	10000	nM	CHEMBL_ACT_25148277

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
psychotic disorder	4	MONDO:0005485	EFO:0005407

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).